Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High – Here’s What Happened

Posted by Stanley Muller on Aug 12th, 2026

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $104.78 and last traded at $102.62, with a volume of 2845965 shares changing hands. The stock had previously closed at $102.62.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HALO. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $83.00 to $110.00 in a research note on Friday, August 7th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Read Our Latest Report on HALO

Halozyme Therapeutics Price Performance

The stock’s fifty day simple moving average is $77.89 and its two-hundred day simple moving average is $71.92. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The company has a market capitalization of $11.65 billion, a price-to-earnings ratio of 30.63, a PEG ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same period in the previous year, the business posted $1.54 EPS. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,103 shares of company stock valued at $3,142,896 over the last quarter. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Empowered Funds LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter valued at $755,000. Acadian Asset Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter worth about $195,000. Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,448 shares during the period. EverSource Wealth Advisors LLC lifted its position in Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its position in Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 650 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.